文献速递流行病学与生物统计临床试验与 GCP

前瞻性个体患者数据荟萃分析:评估恢复期血浆治疗COVID-19

Prospective individual patient data meta-analysis: Evaluating convalescent plasma for COVID-19.
PubMed 文献 · Stat Med · 2021-06-23

本文提出一种创新方法,将多个未组成站点的正在进行的随机对照试验(RCT)的患者水平数据进行合并。作者给出了针对恢复期血浆(CP)治疗COVID-19的前瞻性个体患者数据(IPD)荟萃分析(MA)的统计分析计划,采用自适应贝叶斯方法通过后验概率持续监测累积的合并数据以评估安全性、有效性及危害。该框架可推广至其他疗法和疾病背景的RCT数据合并。

要点

  • 采用自适应贝叶斯方法持续监测合并数据的安全性、有效性与危害
  • 前瞻性IPD荟萃分析可合并未组成站点的多个在研RCT数据
  • 该框架可推广至其他疗法与疾病背景以加速获得答案

核心结论

  • 提出一种前瞻性个体患者数据荟萃分析框架,用于合并多个正在进行的RCT数据并持续监测恢复期血浆治疗COVID-19的安全性与有效性

研究设计与样本

  • 本文提出一种创新方法,将多个未配置为站点网络的正在进行的随机对照试验(RCT)的患者水平数据进行合并。
  • 作者给出了针对恢复期血浆(CP)治疗COVID-19的前瞻性个体患者数据(IPD)荟萃分析(MA)的统计分析计划。
  • 采用自适应贝叶斯方法,通过后验概率持续监测累积的合并数据以评估安全性、有效性和危害。

主要发现

  • 采用自适应贝叶斯方法可通过后验概率对累积合并数据进行安全性、有效性和危害的持续监测。
  • 该框架一般适用于合并其他疗法和疾病背景下RCT的数据,以便在数周或数月而非数年内获得答案。

临床怎么用

  • 对于因疫情地点快速变化而面临招募目标风险的多个在研RCT,可考虑采用前瞻性IPD荟萃分析合并患者水平数据。
  • 可采用自适应贝叶斯方法通过后验概率持续监测合并数据的安全性、有效性和危害。

局限性

  • 原文未报告具体样本量、效应量、置信区间或P值等数值结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the world faced the devastation of the COVID-19 pandemic in late 2019 and early 2020, numerous clinical trials were initiated in many locations in an effort to establish the efficacy (or lack thereof) of potential treatments. As the pandemic has been shifting locations rapidly, individual studies have been at risk of failing to meet recruitment targets because of declining numbers of eligible patients with COVID-19 encountered at participating sites. It has become clear that it might take several more COVID-19 surges at the same location to achieve full enrollment and to find answers about what treatments are effective for this disease. This paper proposes an innovative approach for pooling patient-level data from multiple ongoing randomized clinical trials (RCTs) that have not been configured as a network of sites. We present the statistical analysis plan of a prospective individual patient data (IPD) meta-analysis (MA) from ongoing RCTs of convalescent plasma (CP). We employ an adaptive Bayesian approach for continuously monitoring the accumulating pooled data via posterior probabilities for safety, efficacy, and harm. Although we focus on RCTs for CP and address specific challenges related to CP treatment for COVID-19, the proposed framework is generally applicable to pooling data from RCTs for other therapies and disease settings in order to find answers in weeks or months, rather than years.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Goldfeld KS, Wu D, Tarpey T, et al. Prospective individual patient data meta-analysis: Evaluating convalescent plasma for COVID-19. Stat Med. 2021. PMID: 34164838. doi:10.1002/sim.9115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。